Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB

Axe Cap view

Healthcare ETFs: Stability vs. Biotech Growth

Comparing Vanguard's broad healthcare exposure to iShares' biotech-focused volatility.

South African investors eyeing healthcare can learn from Vanguard's Health Care ETF (VHT) and iShares Biotechnology ETF (IBB). VHT offers a diversified basket across the healthcare sector, trading at a low cost and paying a modest dividend. Its steady profile suits those who prefer less volatility, which fits well with SA’s risk-averse pockets, especially during rand fluctuations. In contrast, IBB’s biotech focus delivers exciting returns but with dramatic ups and downs—a tough ride if the rand weakens or local risk appetite tightens. Considering local stocks, SASOL’s health exposure is limited, but global healthcare leaders in VHT provide indirect opportunities. If you want growth, IBB is tempting but lean into it only if you can stomach volatility and currency swings. A potential setback for VHT buyers is that broad diversification might dull gains when biotech innovation surges, which could benefit IBB. this is just our opinion and not financial advice